Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy

Annals of Surgical Oncology

Volumn 22, Issue 7, 2015, Pages 2387-2394

  Plotti, Francesco ^a   Scaletta, Giuseppe ^a   Aloisi, Alessia ^a   Luvero, Daniela ^a   Capriglione, Stella ^a   Miranda, Andrea ^a   Montera, Roberto ^a,b   De Cicco Nardone, Carlo ^a   Terranova, Corrado ^a   Angioli, Roberto ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; BLOOD VESSEL INJURY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RECURRENCE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE INTERVAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; INTESTINE INJURY; LAPAROSCOPY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PELVIS ABSCESS; PEROPERATIVE COMPLICATION; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; SIDE EFFECT; SOCIAL INTERACTION; THROMBOSIS; CANCER STAGING; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84930482389     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4263-8     Document Type: Article

References (36)

1. American Cancer Society. Cancer facts and figures 2013. Atlanta: American Cancer Society, 2013.
2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2003;83(Suppl):135–66.
4. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.
5. Al Rawahi T, Lopes AD, Bristow RE. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;28:2.
6. Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100:455–61.
7. Dindo D, Dematrtines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and result of a survey. Ann Surg. 2004;240:205–13.
8. World Health Organization. WHO handbook for reporting results of cancer treatment (offset publication no. 48). Geneva: World Health Organization; 1979:16–21.
9. Bjordal K, deGraeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (The EORTC QLQ-H&N35). Eur J Cancer. 2000;36:213–9.
10. Greimel E, Bottomley A, Cull A, et al; EORTC Quality of Life Group and the Quality of Life Unit. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402–8. Published correction appears in Eur J Cancer. 2003;39(17):2570.
11. Scott NW, Fayers PM. The EORTC QLQ_C30 scoring manual. 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
12. Gadducci A, Lacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79(3):344–9.
13. Gungor M, Ortac F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97(1):74–9.
14. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol. 2006;13(12):1702–10.
15. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95(2):273–80.
16. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686–90.
17. Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106(3):482–7.
18. Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010; (6).
19. Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5.
20. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–5.
21. Cella D. What do global quality-of-life questions really measure? Insights from Hobday et al and the “do something” rule. J Clin Oncol. 2003;21(16): 3178–9.
22. WHO. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993;2(2):153–9.
23. Angioli R, Plotti F, Aloisi A, et al. Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life? Int J Gynecol Cancer. 2013;23(3):442–7.
24. Angioli R, Plotti F, Cafà EV, et al. Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):539–43.
25. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33:1025–30.
26. Eton D, Fairclough D, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.
27. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol. 1992;10:1833–8.
28. Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997;6:151–8.
29. Sugarbaker PH, Barofsky I, Rosenberg SA, et al. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery. 1982;91:17–23.
30. Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178–86.
31. Zamurovic M. Ovarian carcinoma patients–life quality analysis in the postoperative period. How to improve it? Eur J Gynaecol Oncol. 2010;31(6):672–4.
32. Woelber L, Jung S, Eulenburg C, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:583–8.
33. Vernooij F, Heintz AP, Coebergh JW, et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009;112:455–61.
34. Bristow RE, Palis BE, Chi DS, et al. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262–7.
35. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289–95.
36. Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.